Author

T. Semple

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

M. Zethoven· 2 shared A. R. Green· 1 shared A. Wei· 1 shared B. T. Kile· 1 shared C. J. Kearney· 1 shared D. D. De Carvalho· 1 shared D. J. Byrne· 1 shared D. Lesche· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Zethoven

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phylogenetic analysis of paired breast carcinomas identifies genetic events associated with clonal recurrence and invasive progression

T. Kader, M. Zethoven, S. Mahale, H. Saunders, L. Tjoeka, R. Lehmann, M. Jayawardane, J.-M. Pang, D. Lesche, N. Rajan, T. Semple, J. E. A. Lee, R. Lupat, D. J. Byrne, S. Hughes, , K. L. Gorringe

The paper analyzes paired breast carcinomas to determine if recurrences are clonal or new tumors, finding 7% are non-clonal by whole exome sequencing.

bioRxiv · May 19, 2024Cancer Biology

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit

J. Salmon, I. Todorovski, S. J. Vervoort, K. L. Stanley, C. J. Kearney, L. Martelotto, F. Rossello, T. Semple, G. Mir Arnau, M. Zethoven, M. Bots, E. Vidacs, K. McArthur, E. Gressier, N. De Weerd, , R. W. Johnstone

The paper shows that inhibiting HDACs in AML promotes type I IFN production by pDCs, enhancing anti-tumor immunity and therapeutic benefit.

bioRxiv · Aug 23, 2020 · PreprintCancer Biology